A comprehensive view of Janssen Pharmaceutical Companies. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer Wellness Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Johnson & Johnson seeks FDA approval for SPRAVATO® as monotherapy for treatment-resistant depression; submission based on Phase 4 data showing rapid depressive symptom improvement within 24 hours
Published: July 22, 2024 by Janssen Pharmaceutical Companies
Johnson & Johnson reports enhanced Q2 2024 earnings, marks pipeline milestones and new approvals; company strengthens market position amidst commitment to developing treatments
Published: July 19, 2024 by Industry Intelligence Inc.
Janssen Pharmaceutical Companies Targets Unmet Needs in Mental Health with FDA Submission for Treatment-Resistant Depression Monotherapy
Published: July 18, 2024 by Industry Intelligence Inc.
Johnson & Johnson completes $1.25 billion acquisition of Yellow Jersey Therapeutics; gains NM26, a Phase 2-ready bispecific antibody for atopic dermatitis and other immune diseases
Published: July 11, 2024 by Janssen Pharmaceutical Companies
Janssen spearheads innovations in cancer with chemotherapy-free NSCLC regimen; company champions transgender-inclusive protocols in prostate cancer and presents new data on neurological disorders at EAN 2024
Published: June 29, 2024 by Industry Intelligence Inc.

Ask us about our Consumer Wellness market view

Trending Chart

Interactive chart with headline count